Latest News

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

28 September 2022

  • Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster exhibit
  • Howard L. Weiner, M.D. of Brigham...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

23 September 2022

New York, September 23, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical...

Read more

Article: ALS Association Funds Study of Foralumab Nasal Spray

22 September 2022

ALS News Today published an article about the ALS Association funding a study into Foralumab Nasal Spray

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

21 September 2022

New York, September 21, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...

Read more

Article: Second SPMS Patient Given Foralumab Continues to Improve

21 September 2022

Multiple Sclerosis News Today has published an article providing an update on the second SPMS patient given Foralumab

Read more

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

20 September 2022

TLSA today announced that the second patient (“EA2”) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal foralumab has shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS), a standard clinical assessment.

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

16 September 2022

New York, September 16, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...

Read more

Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis

15 September 2022

Prestigious ALS Association grant awarded to BWH to study the utility of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

09 September 2022

New York, September 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

25 August 2022

New York, August 25, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...

Read more

Page 2 of 24 Previous Next